URUS completed the acquisition of Trans Ova Genetics from Precigen for $180m.

URUS, a holding company with cooperative and private ownership, completed the acquisition of Trans Ova Genetics, an animal reproductive technologies company, from Precigen, a biotechnology company, for $180m. "We believe this transaction will support Precigen's mission as a premier cell and gene therapy company laser focused on the rapid development of our top clinical assets to maximize shareholder value and potentially improve the way devastating diseases like cancer are treated. I am proud of Precigen management and the Trans Ova team for successfully leading the financial turnaround of Trans Ova operations to maximize the value of this asset over the last two years. We expect to have the capacity to pay the convertible notes upon maturity and to focus on fast regulatory paths for our healthcare portfolio," Helen Sabzevari, Precigen President and CEO.